13 results about "Amyloid Depositions" patented technology

The invention belongs to the technical field of biological medicine, and particularly relates to an extracellular vesicle drug delivery system, a preparation method thereof and application of the extracellular vesicle drug delivery system in treatment of Alzheimer's disease. According to the invention, one or more of stilbene glucoside, emodin, kaempferol, resveratrol and quercetin are used for regulating and controlling the expression of miRNA (micro Ribonucleic Acid) related to the disease progress in the extracellular vesicles, and the result shows that one or more of miR-let-7c-5p, miR-486-5p, miR-132-3p, miR-160b and miR-129-5p is remarkably up-regulated, and one or more of miR-342-3p, miR-16-5p and miR-125b-5p is remarkably down-regulated. The regulated extracellular vesicles can be used for treating Alzheimer's disease, relieving Tau protein abnormal phosphorylation, reducing amyloid protein beta deposition, inhibiting microglial cell activation, protecting neuronal cells and relieving memory deficits.

It is provided an anti-Aβ34 antibody and its use for diagnosing Alzheimer's disease in a patient, comprising obtaining a sample from the patient, detecting the level of Aβ34 in the sample by contacting the sample with the anti-Aβ34 antibody and detecting binding between Aβ34 and the antibody, and diagnosing the patient with Alzheimer's disease when the presence of Aβ34 in the sample is detected, alone or in combination with detecting an amyloid deposition marker such as Aβ42 and determining the ratio of Aβ34 / Aβ42.

The disclosure provides peptide compositions and immunotherapy compositions comprising an amyloid-beta (Aβ, Abeta) peptide, a tau peptide, and an alpha-synuclein peptide. The disclosure also provides methods of treating or effecting prophylaxis of Alzheimer's disease or other diseases with beta-amyloid deposition in a subject, including methods of clearing deposits, inhibiting or reducing aggregation of Aβ and tau and an alpha-synuclein, blocking the uptake by neurons, clearing amyloid, and inhibiting propagation of tau seeds and an alpha-synuclein synucleinopathies in a subject having or at risk of developing Alzheimer's disease or other diseases containing tau and amyloid-beta and an alpha-synuclein accumulations. The methods include administering to such patients the compositions comprising an amyloid-beta (Aβ) peptide and a tau peptide and an alpha-synuclein peptide.

The invention discloses a stem cell-negative hydrogen ion compound preparation for treating Alzheimer's disease, and belongs to the technical field of biomedicine, the compound preparation comprises stem cells, a negative hydrogen ion donor, piceatannol glucoside and a pharmaceutically acceptable carrier. Wherein the concentration of the stem cells is 1 * 10 < 6 >-1 * 10 < 8 > / mL, the concentration of the negative hydrogen ion donor is 25-45mg / mL, and the concentration of piceatannol glucoside is 4-8mu g / mL. The composite preparation integrates neural restoration, anti-inflammatory and immunoregulation functions of stem cells, an efficient antioxidant protection effect of a negative hydrogen ion donor and synergistic interaction and safety guarantee effects of piceatannol glucoside. Animal experiments prove that the composite preparation can significantly improve cognitive impairment of Alzheimer's disease model rats and relieve neuroinflammation, oxidative stress and beta-amyloid protein deposition through synergistic anti-inflammatory, anti-oxidation and neuroprotection mechanisms.

The present invention provides a composition and a method for treating a disease associated with amyloid deposits of Aβ in a patient's brain, such as Alzheimer's disease. Such a method involves administering a pharmaceutical composition comprising an immunogenic fragment of Aβ capable of inducing a beneficial immune response in the form of an antibody against Aβ. The immunogenic fragment comprises a linear or polyvalent peptide of Aβ. The pharmaceutical composition comprises an immunogenic fragment chemically linked to a carrier molecule that can be administered together with an ajuvant.

The present application relates to the technical field of Congo red derivative photocatalytic probe application, and particularly relates to a Congo red derivative photocatalytic probe, a preparation method and a use method thereof, comprising a compound I, the compound I is selected from at least one of the Congo red derivative photocatalytic probes, and the Congo red derivative photocatalytic probe comprises two arene, the arene represents an aromatic heterocycle, and the aromatic heterocycle is selected from one of a benzene ring, furan, thiophene and a naphthalene ring. The Congo red derivative photocatalytic probe provided by the present application can specifically label amyloid plaques in AD brain tissue slices, the binding affinity is significantly improved (Kd of Aβ 1‑40 The Congo red derivative photocatalytic probe can reveal the molecular heterogeneity of amyloid deposition and the key regulatory role of the mitochondrial autophagy-lysosome axis, provide a new tool for AD pathological mechanism research, support proteomic analysis and pathological mechanism analysis across brain regions (hippocampus / cortex), and protect the molecular structure and application in the research of neurodegenerative diseases.

The invention provides an application of a BCMA-CD19 bispecific CAR (Chimeric Antigen Receptor)-immune cell in treatment of amyloidosis. Specifically, the invention provides a BCMA-CD19 bispecific CAR or a coding nucleic acid thereof, or a carrier thereof, or an application of a CAR-immune cell thereof, and the BCMA-CD19 bispecific CAR or the coding nucleic acid thereof, or the carrier thereof, or the CAR-immune cell thereof is used for (i) preparing a medicine for preventing and / or treating amyloidosis; and / or (ii) preparation of drugs for alleviating or reversing amyloid deposition. The invention also provides a method for reducing or reversing amyloid protein deposition by using the BCMA-CD19 bispecific CAR or the coding nucleic acid thereof, or the carrier thereof, or the CAR-immune cell thereof, or the pharmaceutical composition, and a method for preventing and / or treating amyloidosis. The BCMA-CD19 bispecific CAR-immune cell provided by the invention has very good safety and effectiveness, and can achieve the purpose of continuously obtaining clinical deep remission treatment for patients with recurrent and refractory amyloidosis.

The invention relates to an A beta-PET brain template construction and quantitative analysis method based on deep learning, and the method comprises the steps: obtaining a PET image preprocessed by a normal participant, namely, an A beta-PET image; performing spatial registration to MNI152, and performing intensity normalization processing, data screening and average calculation to obtain a preliminary A beta-PET brain template image; the screened A beta-PET image is registered to a preliminary A beta-PET brain template image, and a final A beta-PET brain template image is obtained through intensity normalization processing, data screening, average calculation and smoothing processing; calculating a first quantitative parameter to construct a brain amyloid protein deposition data database; and performing spatial registration on the A beta-PET image to be analyzed to the final A beta-PET brain template image, dividing a brain region, calculating a second quantitative parameter, and comparing the second quantitative parameter with the brain amyloid protein deposition data database to complete quantitative analysis. The method has the beneficial effects that a normal A beta-PET brain template data database is established, a matched quantitative amyloid protein deposition analysis process is provided for clinical use, and the registration effect and the diagnosis and treatment efficiency are improved.

The present invention relates to isolated monoclonal antibodies or their antigen-binding moieties that specifically bind to amyloid fibrils and effectively promote the clearance of extracellular amyloid deposits from tissues in vivo, as well as to humanized antibodies having the same properties.

The present application relates to the technical field of medicine, and more particularly to a polypeptide for inhibiting and / or eliminating beta-amyloid aggregation and application thereof. The present application first develops a functional active polypeptide ANI-1 which can act on diseases caused by beta-amyloid aggregation and deposition such as Alzheimer's disease from multiple targets, so as to effectively prevent and treat the diseases. The polypeptide ANI-1 of the present application has the functions of eliminating A beta aggregation, delaying behavioral decline caused by beta-amyloid toxicity (anti-paralysis, promoting movement), inhibiting neurogenic inflammation related to beta-amyloid deposition and enhancing antioxidant defense, has better overall efficacy and neuroprotective potential, and can provide a new idea for developing a multi-target drug for diseases caused by beta-amyloid aggregation and deposition such as Alzheimer's disease.

This invention discloses a bicyclic compound, its intermediate, a preparation method, and its applications. Specifically, it discloses a compound as shown in Formula I, and its pharmaceutically acceptable salt or isotope. The compound of this invention exhibits good binding ability to amyloid protein, a short half-life, and good imaging effect. Furthermore, the compound of this invention can be used to prepare positron emission tomography (PET) agents and can be used for the early diagnosis of amyloid protein deposition-related diseases, such as Alzheimer's disease, and for monitoring the efficacy of drugs.

The Alzheimer's disease diagnosis method using PET-CT images according to the present application can include: a process of generating a standard brain CT template in MNI (Montreal Neurological Institute) space from a CT image calculated by a PET-CT device; a process of calculating a whole cortex volume of interest (VOI) of a plurality of sub-regions in which the deposition of beta amyloid is above a certain value in a cortex ROI (cortex ROI) region based on the above standard brain CT template; and a process of calculating a percentage unit of each of the above plurality of sub-regions based on the amyloid deposition rate (Standardized uptake value ratio, SUVR) of each of the above plurality of sub-regions. 18 F-florbetaben (FBB) 18 F-florbetaben (FBB) 18 F-flutemetamol (FMM) 18 F-flutemetamol (FMM)

The present invention relates to a process for the preparation of a compound (I),and its solid form, which is a modulator of γ-secretase and may be useful for prophylaxis and treatment of a disease associated with the deposition of β-amyloid in the brain, in particular Alzheimer's disease, and other diseases such as cerebral amyloid angiopathy, hereditary cerebral hemorrhage with amyloidosis, Dutch-type (HCHWA-D), multi-infarct dementia, dementia pugilistica and Down syndrome.